Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective.
Spontaneous bacterial peritonitis is a complication of ascitic patients with end-stage liver disease (ESLD); spontaneous fungal peritonitis (SFP) is a complication of ESLD less known and described. ESLD is associated to immunodepression and the resulting increased susceptibility to infections. Recent perspectives of the management of the critically ill patient with ESLD do not specify the rate of isolation of fungi in critically ill patients, not even the antifungals used for the prophylaxis, neither optimal treatment. We reviewed, in order to focus the epidemiology, characteristics, and, considering the high mortality rate of SFP, the use of optimal empirical antifungal therapy the current literature.
Marco Fiore, Department of Anesthesiological, Surgical and Emergency Sciences, Second University of Naples, 80138 Naples, Italy.
Marco
M
Fiore
Marco Fiore, Department of Anesthesiological, Surgical and Emergency Sciences, Second University of Naples, 80138 Naples, Italy.
Sebastiano
S
Leone
D000935:Antifungal Agents / Q000627:therapeutic use; D001201:Ascites / Q000382:microbiology; D001202:Ascitic Fluid / Q000382:microbiology; D001424:Bacterial Infections / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology* / Q000628:therapy; D016638:Critical Illness; D003428:Cross Infection / Q000150:complications; D058625:End Stage Liver Disease / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D009181:Mycoses / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology* / Q000628:therapy; D010538:Peritonitis / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology* / Q000628:therapy; D012307:Risk Factors
D000935:Antifungal Agents
Cirrhosis; Critically ill patient; Fungal ascitis; Life-threatening infections; Nosocomial spontaneous peritonitis; Spontaneous fungal peritonitis
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
16127033
Int J Antimicrob Agents. 2011 Sep;38(3):271-2
21782394
Clin Infect Dis. 2006 Jul 1;43(1):25-31
16758414
World J Gastroenterol. 2015 Sep 28;21(36):10409-17
26420967
Liver Int. 2016 May;36(5):677-87
26474358
Clin Infect Dis. 2015 Apr 1;60(7):997-1006
25520332
Hepatology. 2016 Apr;63(4):1299-309
26084406
BMC Infect Dis. 2014 May 23;14:287
24884471
Aliment Pharmacol Ther. 2012 May;35(10):1199-208
22449290
Eur J Clin Microbiol Infect Dis. 2014 Feb;33(2):259-64
23996048
Clin Mol Hepatol. 2013 Jun;19(2):131-9
23837137
J Hepatol. 2012 Apr;56(4):825-32
22173153
Dig Liver Dis. 2014 Jun;46(6):573-4
24618097
Hepatology. 2016 Sep;64(3):997-8
26754934
Infection. 2009 Feb;37(1):2-8
19169633
Scand J Infect Dis. 2004;36(9):649-55
15370651
Hepatology. 2009 Jun;49(6):2087-107
19475696
Mycoses. 2015 Jul;58(7):387-93
25851525
Aliment Pharmacol Ther. 2015 Apr;41(8):747-57
25703246
Enferm Infecc Microbiol Clin. 2016 Oct;34(8):505-7
26195346
Eur J Clin Microbiol Infect Dis. 2003 Jan;22(1):10-5
12582738
Crit Care. 2011;15(6):R287
22126425
J Gastroenterol Hepatol. 2016 Jun;31(6):1191-5
26676553
Clin Infect Dis. 2009 May 1;48(9):1230-6
19302016
World J Emerg Surg. 2013 Jan 08;8(1):3
23294512
Mycoses. 1999;42 Suppl 2:29-32
10865900
Int J Infect Dis. 2014 Jun;23:69-74
24726663
J Hepatol. 2016 Apr;64(4):986-7
26795829
J Chemother. 2009 Jul;21 Suppl 1:30-5
19622448
J Antimicrob Chemother. 2011 Sep;66(9):2146-51
21700622
J Hepatol. 2014 Jun;60(6):1310-24
24530646